Abstract
INTRODUCTION: Tranexamic acid (TXA) is increasingly used in adult spinal deformity surgeries to minimize blood loss and the necessity for transfusions. METHODS: We conducted a retrospective cohort study involving 641 adults (aged 18 years and older) who underwent elective spinal deformity surgery at a tertiary academic center from July 2013 to December 2021. Patients were categorized based on their TXA regimen (no TXA, bolus-only, infusion-only, or combined bolus and infusion). The outcomes evaluated included estimated blood loss (EBL), the incidence and volume of transfusions, operative duration, postoperative hemoglobin levels on days 1–3, and 90-day thromboembolic events. We employed overlap propensity-score weighting to control for baseline differences. RESULTS: Among 641 adults (mean age 59.9 years; 35.3% male), 268 (41.8%) received TXA (bolus-only 23.9%, infusion-only 28.7%, combined 47.4%), with a median total dose of 21.8 mg/kg (IQR, 15.5–38.3). TXA use reduced intraoperative blood loss by 129 mL (9.7%). The overlap-weighted risk of any allogeneic transfusion was lower with TXA (73.8% vs. 79.4%; RR, 0.51; 95% CI, 0.21–1.26), with no significant change in transfusion volume (–0.11 log-units; 95% CI, –0.25 to 0.02). TXA preserved postoperative hemoglobin (mean Δ 0.43 g/dL [95% CI, 0.19–0.68] at POD 2; 0.42 g/dL [0.18–0.66] at POD 3). Operative time was similar (mean difference 7.7 min; 95% CI, –18.9 to 34.3). There was no increase in 90-day deep vein thrombosis (RR, 0.77; 95% CI, 0.36–1.68) or pulmonary embolism (RR, 0.88; 95% CI, 0.52–1.50) events. Additionally, there was no increase in 90-day cardiovascular events (RR, 0.91; 95% CI, 0.70–1.18), surgical site infection (RR, 1.36; 95% CI, 0.09–21.59), or any complication (RR, 1.06; 95% CI, 0.91–1.23). Dose-response safety analyses, categorizing total TXA into 40 mg/kg, revealed no dose-dependent increase in complications. CONCLUSIONS: Intraoperative TXA, whether administered as a bolus, infusion, or combined regimen, was associated with a significant reduction in blood loss, preservation of postoperative hemoglobin levels, and a non-significant trend toward fewer allogeneic transfusions, without prolonging operative time or increasing 90-day thromboembolic complications. These real-world data affirm TXA’s safety and efficacy as a core component of multimodal blood conservation in major spine surgery and underscore the need for future prospective trials to optimize dosing and administration protocols.